<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;v=2.18.0.post9+e462414&amp;utm_campaign=pubmed-2&amp;utm_medium=rss&amp;ff=20240515061000&amp;fc=20230708114047
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;v=2.18.0.post9+e462414&amp;utm_campaign=pubmed-2&amp;utm_medium=rss&amp;ff=20240515061000&amp;fc=20230708114047" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Wed, 15 May 2024 10:10:03 +0000</lastbuilddate>
<pubDate>Tue, 14 May 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Cardiovascular-Kidney-Metabolic Overlap in Heart Failure with Mildly Reduced or Preserved Ejection Fraction: A Trial-Level Analysis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38744407/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240515061000&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 May 9:S0735-1097(24)07204-8. doi: 10.1016/j.jacc.2024.05.005. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38744407/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240515061000&v=2.18.0.post9+e462414">38744407</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.005>10.1016/j.jacc.2024.05.005</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38744407</guid>
<pubDate>Tue, 14 May 2024 06:00:00 -0400</pubDate>
<dc:creator>John W Ostrominski</dc:creator>
<dc:creator>Brian L Claggett</dc:creator>
<dc:creator>Zi Michael Miao</dc:creator>
<dc:creator>Finnian R Mc Causland</dc:creator>
<dc:creator>Inder S Anand</dc:creator>
<dc:creator>Akshay S Desai</dc:creator>
<dc:creator>Pardeep S Jhund</dc:creator>
<dc:creator>Carolyn S P Lam</dc:creator>
<dc:creator>Marc A Pfeffer</dc:creator>
<dc:creator>Bertram Pitt</dc:creator>
<dc:creator>Faiez Zannad</dc:creator>
<dc:creator>Michael R Zile</dc:creator>
<dc:creator>Antonieta Bomfim Wirtz</dc:creator>
<dc:creator>James Lay-Flurrie</dc:creator>
<dc:creator>Prabhakar Viswanathan</dc:creator>
<dc:creator>John J V McMurray</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:creator>Muthiah Vaduganathan</dc:creator>
<dc:date>2024-05-14</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Cardiovascular-Kidney-Metabolic Overlap in Heart Failure with Mildly Reduced or Preserved Ejection Fraction: A Trial-Level Analysis</dc:title>
<dc:identifier>pmid:38744407</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.005</dc:identifier>
</item>
<item>
<title>The first two blastomeres contribute unequally to the human embryo</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38744282/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240515061000&amp;v=2.18.0.post9+e462414
      <description>Retrospective lineage reconstruction of humans predicts that dramatic clonal imbalances in the body can be traced to the 2-cell stage embryo. However, whether and how such clonal asymmetries arise in the embryo is unclear. Here, we performed prospective lineage tracing of human embryos using live imaging, non-invasive cell labeling, and computational predictions to determine the contribution of each 2-cell stage blastomere to the epiblast (body), hypoblast (yolk sac), and trophectoderm...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 May 9:S0092-8674(24)00455-0. doi: 10.1016/j.cell.2024.04.029. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Retrospective lineage reconstruction of humans predicts that dramatic clonal imbalances in the body can be traced to the 2-cell stage embryo. However, whether and how such clonal asymmetries arise in the embryo is unclear. Here, we performed prospective lineage tracing of human embryos using live imaging, non-invasive cell labeling, and computational predictions to determine the contribution of each 2-cell stage blastomere to the epiblast (body), hypoblast (yolk sac), and trophectoderm (placenta). We show that the majority of epiblast cells originate from only one blastomere of the 2-cell stage embryo. We observe that only one to three cells become internalized at the 8-to-16-cell stage transition. Moreover, these internalized cells are more frequently derived from the first cell to divide at the 2-cell stage. We propose that cell division dynamics and a cell internalization bottleneck in the early embryo establish asymmetry in the clonal composition of the future human body.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38744282/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240515061000&v=2.18.0.post9+e462414">38744282</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.04.029>10.1016/j.cell.2024.04.029</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38744282</guid>
<pubDate>Tue, 14 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Sergi Junyent</dc:creator>
<dc:creator>Maciej Meglicki</dc:creator>
<dc:creator>Roman Vetter</dc:creator>
<dc:creator>Rachel Mandelbaum</dc:creator>
<dc:creator>Catherine King</dc:creator>
<dc:creator>Ekta M Patel</dc:creator>
<dc:creator>Lisa Iwamoto-Stohl</dc:creator>
<dc:creator>Clare Reynell</dc:creator>
<dc:creator>Dong-Yuan Chen</dc:creator>
<dc:creator>Patrizia Rubino</dc:creator>
<dc:creator>Nabil Arrach</dc:creator>
<dc:creator>Richard J Paulson</dc:creator>
<dc:creator>Dagmar Iber</dc:creator>
<dc:creator>Magdalena Zernicka-Goetz</dc:creator>
<dc:date>2024-05-14</dc:date>
<dc:source>Cell</dc:source>
<dc:title>The first two blastomeres contribute unequally to the human embryo</dc:title>
<dc:identifier>pmid:38744282</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.04.029</dc:identifier>
</item>
<item>
<title>Osr2 functions as a biomechanical checkpoint to aggravate CD8&lt;sup>;+&lt;/sup>; T cell exhaustion in tumor</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38744281/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240515061000&amp;v=2.18.0.post9+e462414
      <description>Alterations in extracellular matrix (ECM) architecture and stiffness represent hallmarks of cancer. Whether the biomechanical property of ECM impacts the functionality of tumor-reactive CD8^(+) T cells remains largely unknown. Here, we reveal that the transcription factor (TF) Osr2 integrates biomechanical signaling and facilitates the terminal exhaustion of tumor-reactive CD8^(+) T cells. Osr2 expression is selectively induced in the terminally exhausted tumor-specific CD8^(+) T cell subset by...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 May 9:S0092-8674(24)00448-3. doi: 10.1016/j.cell.2024.04.023. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Alterations in extracellular matrix (ECM) architecture and stiffness represent hallmarks of cancer. Whether the biomechanical property of ECM impacts the functionality of tumor-reactive CD8<sup>+</sup> T cells remains largely unknown. Here, we reveal that the transcription factor (TF) Osr2 integrates biomechanical signaling and facilitates the terminal exhaustion of tumor-reactive CD8<sup>+</sup> T cells. Osr2 expression is selectively induced in the terminally exhausted tumor-specific CD8<sup>+</sup> T cell subset by coupled T cell receptor (TCR) signaling and biomechanical stress mediated by the Piezo1/calcium/CREB axis. Consistently, depletion of Osr2 alleviates the exhaustion of tumor-specific CD8<sup>+</sup> T cells or CAR-T cells, whereas forced Osr2 expression aggravates their exhaustion in solid tumor models. Mechanistically, Osr2 recruits HDAC3 to rewire the epigenetic program for suppressing cytotoxic gene expression and promoting CD8<sup>+</sup> T cell exhaustion. Thus, our results unravel Osr2 functions as a biomechanical checkpoint to exacerbate CD8<sup>+</sup> T cell exhaustion and could be targeted to potentiate cancer immunotherapy.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38744281/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240515061000&v=2.18.0.post9+e462414">38744281</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.04.023>10.1016/j.cell.2024.04.023</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38744281</guid>
<pubDate>Tue, 14 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Jinjia Zhang</dc:creator>
<dc:creator>Junhong Li</dc:creator>
<dc:creator>Yongqiang Hou</dc:creator>
<dc:creator>Yao Lin</dc:creator>
<dc:creator>Hao Zhao</dc:creator>
<dc:creator>Yiran Shi</dc:creator>
<dc:creator>Kaiyun Chen</dc:creator>
<dc:creator>Cheng Nian</dc:creator>
<dc:creator>Jiayu Tang</dc:creator>
<dc:creator>Lei Pan</dc:creator>
<dc:creator>Yunzhi Xing</dc:creator>
<dc:creator>Huan Gao</dc:creator>
<dc:creator>Bingying Yang</dc:creator>
<dc:creator>Zengfang Song</dc:creator>
<dc:creator>Yao Cheng</dc:creator>
<dc:creator>Yue Liu</dc:creator>
<dc:creator>Min Sun</dc:creator>
<dc:creator>Yueyue Linghu</dc:creator>
<dc:creator>Jiaxin Li</dc:creator>
<dc:creator>Haitao Huang</dc:creator>
<dc:creator>Zhangjian Lai</dc:creator>
<dc:creator>Zhien Zhou</dc:creator>
<dc:creator>Zifeng Li</dc:creator>
<dc:creator>Xiufeng Sun</dc:creator>
<dc:creator>Qinghua Chen</dc:creator>
<dc:creator>Dongxue Su</dc:creator>
<dc:creator>Wengang Li</dc:creator>
<dc:creator>Zhihai Peng</dc:creator>
<dc:creator>Pingguo Liu</dc:creator>
<dc:creator>Wei Chen</dc:creator>
<dc:creator>Hongling Huang</dc:creator>
<dc:creator>Yixin Chen</dc:creator>
<dc:creator>Bailong Xiao</dc:creator>
<dc:creator>Lilin Ye</dc:creator>
<dc:creator>Lanfen Chen</dc:creator>
<dc:creator>Dawang Zhou</dc:creator>
<dc:date>2024-05-14</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Osr2 functions as a biomechanical checkpoint to aggravate CD8&lt;sup>;+&lt;/sup>; T cell exhaustion in tumor</dc:title>
<dc:identifier>pmid:38744281</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.04.023</dc:identifier>
</item>
<item>
<title>Vertebrate centromeres in mitosis are functionally bipartite structures stabilized by cohesin</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38744280/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240515061000&amp;v=2.18.0.post9+e462414
      <description>Centromeres are scaffolds for the assembly of kinetochores that ensure chromosome segregation during cell division. How vertebrate centromeres obtain a three-dimensional structure to accomplish their primary function is unclear. Using super-resolution imaging, capture-C, and polymer modeling, we show that vertebrate centromeres are partitioned by condensins into two subdomains during mitosis. The bipartite structure is found in human, mouse, and chicken cells and is therefore a fundamental...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 May 8:S0092-8674(24)00409-4. doi: 10.1016/j.cell.2024.04.014. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Centromeres are scaffolds for the assembly of kinetochores that ensure chromosome segregation during cell division. How vertebrate centromeres obtain a three-dimensional structure to accomplish their primary function is unclear. Using super-resolution imaging, capture-C, and polymer modeling, we show that vertebrate centromeres are partitioned by condensins into two subdomains during mitosis. The bipartite structure is found in human, mouse, and chicken cells and is therefore a fundamental feature of vertebrate centromeres. Super-resolution imaging and electron tomography reveal that bipartite centromeres assemble bipartite kinetochores, with each subdomain binding a distinct microtubule bundle. Cohesin links the centromere subdomains, limiting their separation in response to spindle forces and avoiding merotelic kinetochore-spindle attachments. Lagging chromosomes during cancer cell divisions frequently have merotelic attachments in which the centromere subdomains are separated and bioriented. Our work reveals a fundamental aspect of vertebrate centromere biology with implications for understanding the mechanisms that guarantee faithful chromosome segregation.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38744280/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240515061000&v=2.18.0.post9+e462414">38744280</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.04.014>10.1016/j.cell.2024.04.014</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38744280</guid>
<pubDate>Tue, 14 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Carlos Sacristan</dc:creator>
<dc:creator>Kumiko Samejima</dc:creator>
<dc:creator>Lorena Andrade Ruiz</dc:creator>
<dc:creator>Moonmoon Deb</dc:creator>
<dc:creator>Maaike L A Lambers</dc:creator>
<dc:creator>Adam Buckle</dc:creator>
<dc:creator>Chris A Brackley</dc:creator>
<dc:creator>Daniel Robertson</dc:creator>
<dc:creator>Tetsuya Hori</dc:creator>
<dc:creator>Shaun Webb</dc:creator>
<dc:creator>Robert Kiewisz</dc:creator>
<dc:creator>Tristan Bepler</dc:creator>
<dc:creator>Eloïse van Kwawegen</dc:creator>
<dc:creator>Patrik Risteski</dc:creator>
<dc:creator>Kruno Vukušić</dc:creator>
<dc:creator>Iva M Tolić</dc:creator>
<dc:creator>Thomas Müller-Reichert</dc:creator>
<dc:creator>Tatsuo Fukagawa</dc:creator>
<dc:creator>Nick Gilbert</dc:creator>
<dc:creator>Davide Marenduzzo</dc:creator>
<dc:creator>William C Earnshaw</dc:creator>
<dc:creator>Geert J P L Kops</dc:creator>
<dc:date>2024-05-14</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Vertebrate centromeres in mitosis are functionally bipartite structures stabilized by cohesin</dc:title>
<dc:identifier>pmid:38744280</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.04.014</dc:identifier>
</item>
<item>
<title>Stepping into the Future of Care for Patients with PAD</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38743808/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240515061000&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 May 14. doi: 10.1161/CIRCULATIONAHA.124.069449. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38743808/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240515061000&v=2.18.0.post9+e462414">38743808</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069449>10.1161/CIRCULATIONAHA.124.069449</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38743808</guid>
<pubDate>Tue, 14 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Marc P Bonaca</dc:creator>
<dc:creator>Naomi M Hamburg</dc:creator>
<dc:creator>Mark A Creager</dc:creator>
<dc:date>2024-05-14</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Stepping into the Future of Care for Patients with PAD</dc:title>
<dc:identifier>pmid:38743808</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069449</dc:identifier>
</item>
<item>
<title>2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38743805/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240515061000&amp;v=2.18.0.post9+e462414
      <description>AIM: The "2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease" provides recommendations to guide clinicians in the treatment of patients with lower extremity peripheral artery disease across its multiple clinical presentation subsets (ie, asymptomatic, chronic symptomatic, chronic limb-threatening ischemia, and acute limb ischemia).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 May 14. doi: 10.1161/CIR.0000000000001251. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">AIM: The "2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease" provides recommendations to guide clinicians in the treatment of patients with lower extremity peripheral artery disease across its multiple clinical presentation subsets (ie, asymptomatic, chronic symptomatic, chronic limb-threatening ischemia, and acute limb ischemia).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A comprehensive literature search was conducted from October 2020 to June 2022, encompassing studies, reviews, and other evidence conducted on human subjects that was published in English from PubMed, EMBASE, the Cochrane Library, CINHL Complete, and other selected databases relevant to this guideline. Additional relevant studies, published through May 2023 during the peer review process, were also considered by the writing committee and added to the evidence tables where appropriate.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">STRUCTURE: Recommendations from the "2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease" have been updated with new evidence to guide clinicians. In addition, new recommendations addressing comprehensive care for patients with peripheral artery disease have been developed.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38743805/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240515061000&v=2.18.0.post9+e462414">38743805</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001251>10.1161/CIR.0000000000001251</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38743805</guid>
<pubDate>Tue, 14 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Heather L Gornik</dc:creator>
<dc:creator>Herbert D Aronow</dc:creator>
<dc:creator>Philip P Goodney</dc:creator>
<dc:creator>Shipra Arya</dc:creator>
<dc:creator>Luke Packard Brewster</dc:creator>
<dc:creator>Lori Byrd</dc:creator>
<dc:creator>Venita Chandra</dc:creator>
<dc:creator>Douglas E Drachman</dc:creator>
<dc:creator>Jennifer M Eaves</dc:creator>
<dc:creator>Jonathan K Ehrman</dc:creator>
<dc:creator>John N Evans</dc:creator>
<dc:creator>Thomas S D Getchius</dc:creator>
<dc:creator>J Antonio Gutiérrez</dc:creator>
<dc:creator>Beau M Hawkins</dc:creator>
<dc:creator>Connie N Hess</dc:creator>
<dc:creator>Karen J Ho</dc:creator>
<dc:creator>W Schuyler Jones</dc:creator>
<dc:creator>Esther S H Kim</dc:creator>
<dc:creator>Scott Kinlay</dc:creator>
<dc:creator>Lee Kirksey</dc:creator>
<dc:creator>Debra Kohlman-Trigoboff</dc:creator>
<dc:creator>Chandler A Long</dc:creator>
<dc:creator>Amy West Pollak</dc:creator>
<dc:creator>Saher S Sabri</dc:creator>
<dc:creator>Lawrence B Sadwin</dc:creator>
<dc:creator>Eric A Secemsky</dc:creator>
<dc:creator>Maya Serhal</dc:creator>
<dc:creator>Mehdi H Shishehbor</dc:creator>
<dc:creator>Diane Treat-Jacobson</dc:creator>
<dc:creator>Luke R Wilkins</dc:creator>
<dc:date>2024-05-14</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines</dc:title>
<dc:identifier>pmid:38743805</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001251</dc:identifier>
</item>
<item>
<title>B-type natriuretic peptide levels predict long-term mortality in a large cohort of adults with congenital heart disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38743452/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240515061000&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Baseline BNP and temporal BNP changes are both significantly associated with all-cause mortality in ACHD independent of congenital heart disease diagnosis, complexity, anatomic/haemodynamic features, and/or systolic systemic ventricular function. B-type natriuretic peptide levels represent an easy to obtain and inexpensive marker conveying prognostic information and should be used for the routine surveillance of patients with ACHD.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 May 14:ehae254. doi: 10.1093/eurheartj/ehae254. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Many adult patients with congenital heart disease (ACHD) are still afflicted by premature death. Previous reports suggested natriuretic peptides may identify ACHD patients with adverse outcome. The study investigated prognostic power of B-type natriuretic peptide (BNP) across the spectrum of ACHD in a large contemporary cohort.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The cohort included 3392 consecutive ACHD patients under long-term follow-up at a tertiary ACHD centre between 2006 and 2019. The primary study endpoint was all-cause mortality.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 11 974 BNP measurements were analysed. The median BNP at baseline was 47 (24-107) ng/L. During a median follow-up of 8.6 years (29 115 patient-years), 615 (18.1%) patients died. On univariable and multivariable analysis, baseline BNP [hazard ratio (HR) 1.16, 95% confidence interval (CI) 1.15-1.18 and HR 1.13, 95% CI 1.08-1.18, respectively] and temporal changes in BNP levels (HR 1.22, 95% CI 1.19-1.26 and HR 1.19, 95% CI 1.12-1.26, respectively) were predictive of mortality (P &lt; .001 for both) independently of congenital heart disease diagnosis, complexity, anatomic/haemodynamic features, and/or systolic systemic ventricular function. Patients within the highest quartile of baseline BNP (>;107 ng/L) and those within the highest quartile of temporal BNP change (>;35 ng/L) had significantly increased risk of death (HR 5.8, 95% CI 4.91-6.79, P &lt; .001, and HR 3.6, 95% CI 2.93-4.40, P &lt; .001, respectively).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Baseline BNP and temporal BNP changes are both significantly associated with all-cause mortality in ACHD independent of congenital heart disease diagnosis, complexity, anatomic/haemodynamic features, and/or systolic systemic ventricular function. B-type natriuretic peptide levels represent an easy to obtain and inexpensive marker conveying prognostic information and should be used for the routine surveillance of patients with ACHD.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38743452/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240515061000&v=2.18.0.post9+e462414">38743452</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae254>10.1093/eurheartj/ehae254</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38743452</guid>
<pubDate>Tue, 14 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Yusuke Yumita</dc:creator>
<dc:creator>Zhuoyuan Xu</dc:creator>
<dc:creator>Gerhard-Paul Diller</dc:creator>
<dc:creator>Aleksander Kempny</dc:creator>
<dc:creator>Isma Rafiq</dc:creator>
<dc:creator>Claudia Montanaro</dc:creator>
<dc:creator>Wei Li</dc:creator>
<dc:creator>Hong Gu</dc:creator>
<dc:creator>Konstantinos Dimopoulos</dc:creator>
<dc:creator>Koichiro Niwa</dc:creator>
<dc:creator>Michael A Gatzoulis</dc:creator>
<dc:creator>Margarita Brida</dc:creator>
<dc:date>2024-05-14</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>B-type natriuretic peptide levels predict long-term mortality in a large cohort of adults with congenital heart disease</dc:title>
<dc:identifier>pmid:38743452</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae254</dc:identifier>
</item>
<item>
<title>Effect of Cangrelor on Infarct Size in ST-Segment Elevation Myocardial Infarction Treated By Primary Percutaneous Coronary Intervention: A Randomized Controlled Trial (The PITRI Trial)</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38742915/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240515061000&amp;v=2.18.0.post9+e462414
      <description>Background: The administration of intravenous cangrelor at reperfusion achieves faster onset of platelet P2Y12 inhibition than oral ticagrelor and has been shown to reduce myocardial infarct (MI) size in the pre-clinical setting. We hypothesized that the administration of cangrelor at reperfusion will reduce MI size and prevent microvascular obstruction (MVO) in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI). Methods:...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 May 14. doi: 10.1161/CIRCULATIONAHA.124.068938. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"><b>Background:</b> The administration of intravenous cangrelor at reperfusion achieves faster onset of platelet P2Y12 inhibition than oral ticagrelor and has been shown to reduce myocardial infarct (MI) size in the pre-clinical setting. We hypothesized that the administration of cangrelor at reperfusion will reduce MI size and prevent microvascular obstruction (MVO) in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI). <b>Methods:</b> This was a Phase 2, multi-center, randomized, double-blind, placebo controlled clinical trial conducted between November 2017 to November 2021 in six cardiac centers in Singapore (NCT03102723). Patients were randomized to receive either cangrelor or placeboinitiated prior to the PPCI procedure on top of oral ticagrelor. The key exclusion criteria included: presenting &lt;6 hours of symptom onset, prior MI and stroke or transient ischemic attack; on concomitant oral anticoagulants; and a contraindication for cardiovascular magnetic resonance (CMR). The primary efficacy endpoint was acute MI size by CMR within the first week expressed as percentage of the left ventricle mass ( %LVmass). MVO was identified as areas of dark core of hypoenhancement within areas of late gadolinium enhancement. The primary safety endpoint was Bleeding Academic Research Consortium (BARC)-defined major bleeding in the first 48 hours. Continuous variables were compared by Mann-Whitney U test [reported as median (1<sup>st</sup> quartile- 3<sup>rd</sup> quartile)] and categorical variables were compared by Fisher's exact test. A 2-sided P&lt;0.05 was considered statistically significant. <b>Results:</b> Of 209 recruited patients, 164 patients (78% ) completed the acute CMR scan. There were no significant differences in acute MI size [placebo: 14.9 (7.3 - 22.6) %LVmass versus cangrelor: 16.3 (9.9 - 24.4)%LVmass, P=0.40] or the incidence [placebo: 48% versus cangrelor: 47%, P=0.99] and extent of MVO [placebo:1.63 (0.60 - 4.65)%LVmass versus cangrelor: 1.18 (0.53 - 3.37)%LVmass, P=0.46] between placebo and cangrelor despite a two-fold decrease in platelet reactivity with cangrelor. There were no BARC-defined major bleeding events in either group in the first 48 hours. <b>Conclusions:</b> Cangrelor administered at time of PPCI did not reduce acute MI size or prevent MVO in STEMI patients given oral ticagrelor despite a significant reduction of platelet reactivity during the PCI procedure.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38742915/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240515061000&v=2.18.0.post9+e462414">38742915</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.068938>10.1161/CIRCULATIONAHA.124.068938</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38742915</guid>
<pubDate>Tue, 14 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Heerajnarain Bulluck</dc:creator>
<dc:creator>Jun Hua Chong</dc:creator>
<dc:creator>Jennifer Bryant</dc:creator>
<dc:creator>Annitha Annathurai</dc:creator>
<dc:creator>Ping Chai</dc:creator>
<dc:creator>Mervyn Chan</dc:creator>
<dc:creator>Ashish Chawla</dc:creator>
<dc:creator>Chee Yang Chin</dc:creator>
<dc:creator>Yiu-Cho Chung</dc:creator>
<dc:creator>Fei Gao</dc:creator>
<dc:creator>Hee Hwa Ho</dc:creator>
<dc:creator>Andrew Fu Wah Ho</dc:creator>
<dc:creator>John Hoe</dc:creator>
<dc:creator>Syed Saqib Imran</dc:creator>
<dc:creator>Chi-Hang Lee</dc:creator>
<dc:creator>Benji Lim</dc:creator>
<dc:creator>Soo Teik Lim</dc:creator>
<dc:creator>Swee Han Lim</dc:creator>
<dc:creator>Boon Wah Liew</dc:creator>
<dc:creator>Patrick Lim Zhan Yun</dc:creator>
<dc:creator>Marcus Eng Hock Ong</dc:creator>
<dc:creator>Valeria Paradies</dc:creator>
<dc:creator>Xuan Ming Pung</dc:creator>
<dc:creator>Julian Cheong Kiat Tay</dc:creator>
<dc:creator>Lynette Teo</dc:creator>
<dc:creator>Boon Ping Ting</dc:creator>
<dc:creator>Aaron Wong</dc:creator>
<dc:creator>Evelyn Wong</dc:creator>
<dc:creator>Timothy Watson</dc:creator>
<dc:creator>Mark Y Chan</dc:creator>
<dc:creator>Yeo Khung Keong</dc:creator>
<dc:creator>Jack W C Tan</dc:creator>
<dc:creator>Derek J Hausenloy</dc:creator>
<dc:creator>PITRI Investigators</dc:creator>
<dc:date>2024-05-14</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Effect of Cangrelor on Infarct Size in ST-Segment Elevation Myocardial Infarction Treated By Primary Percutaneous Coronary Intervention: A Randomized Controlled Trial (The PITRI Trial)</dc:title>
<dc:identifier>pmid:38742915</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.068938</dc:identifier>
</item>
<item>
<title>Periprocedural myocardial infarction after percutaneous coronary intervention and long-term mortality: a meta-analysis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38742545/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240515061000&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: All currently available international definitions of PMI are associated with an increased risk of all-cause death after percutaneous coronary intervention. The magnitude of this latter association varies according to the sensitivity and prognostic relevance of each definition.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 May 14:ehae266. doi: 10.1093/eurheartj/ehae266. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Conflicting data are available regarding the association between periprocedural myocardial infarction (PMI) and mortality following percutaneous coronary intervention. The purpose of this study was to evaluate the incidence and prognostic implication of PMI according to the Universal Definition of Myocardial Infarction (UDMI), the Academic Research Consortium (ARC)-2 definition, and the Society for Cardiovascular Angiography and Interventions (SCAI) definition.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Studies reporting adjusted effect estimates were systematically searched. The primary outcome was all-cause death, while cardiac death was included as a secondary outcome. Studies defining PMI according to biomarker elevation without further evidence of myocardial ischaemia ('ancillary criteria') were included and reported as 'definition-like'. Data were pooled in a random-effect model.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 19 studies and 109 568 patients were included. The incidence of PMI was progressively lower across the UDMI, ARC-2, and SCAI definitions. All PMI definitions were independently associated with all-cause mortality [UDMI: hazard ratio (HR) 1.61, 95% confidence interval (CI) 1.32-1.97; I2 34%; ARC-2: HR 2.07, 95% CI 1.40-3.08, I2 0%; SCAI: HR 3.24, 95% CI 2.36-4.44, I2 78%]. Including ancillary criteria in the PMI definitions were associated with an increased prognostic performance in the UDMI but not in the SCAI definition. Data were consistent after evaluation of major sources of heterogeneity.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: All currently available international definitions of PMI are associated with an increased risk of all-cause death after percutaneous coronary intervention. The magnitude of this latter association varies according to the sensitivity and prognostic relevance of each definition.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38742545/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240515061000&v=2.18.0.post9+e462414">38742545</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae266>10.1093/eurheartj/ehae266</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38742545</guid>
<pubDate>Tue, 14 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Luca Paolucci</dc:creator>
<dc:creator>Fabio Mangiacapra</dc:creator>
<dc:creator>Sara Sergio</dc:creator>
<dc:creator>Annunziata Nusca</dc:creator>
<dc:creator>Carlo Briguori</dc:creator>
<dc:creator>Emanuele Barbato</dc:creator>
<dc:creator>Gian Paolo Ussia</dc:creator>
<dc:creator>Francesco Grigioni</dc:creator>
<dc:date>2024-05-14</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Periprocedural myocardial infarction after percutaneous coronary intervention and long-term mortality: a meta-analysis</dc:title>
<dc:identifier>pmid:38742545</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae266</dc:identifier>
</item>
<item>
<title>Influence of Pathophysiological Patterns of Coronary Artery Disease on Immediate Percutaneous Coronary Intervention Outcomes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38742491/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240515061000&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Pathophysiological CAD patterns distinctly affect the safety and effectiveness of PCI. The PPG showed an excellent predictive capacity for optimal revascularisation and demonstrated added value compared to a FFR measurement.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 May 14. doi: 10.1161/CIRCULATIONAHA.124.069450. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Diffuse coronary artery disease (CAD) impacts the safety and efficacy of percutaneous coronary intervention (PCI). Pathophysiological CAD patterns can be quantified using fractional flow reserve (FFR) pullbacks incorporating the pullback pressure gradient (PPG) calculation. This study aimed to establish the capacity of PPG to predict optimal revascularisation and procedural outcomes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This prospective, investigator-initiated, single-arm, multicentre study enrolled patients with at least one epicardial lesion with an FFR ≤ 0.80 scheduled for PCI. Manual FFR pullbacks were employed to calculate PPG. The primary outcome of optimal revascularisation was defined as a post-PCI FFR ≥ 0.88.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: 993 patients with 1044 vessels were included. The mean FFR was 0.68 ± 0.12, PPG 0.62 ± 0.17, and post-PCI FFR 0.87 ± 0.07. PPG was significantly correlated with the change in FFR after PCI (r=0.65, 95% CI 0.61-0.69, p&lt;0.001) and demonstrated excellent predicted capacity for optimal revascularisation (AUC 0.82, 95% CI 0.79-0.84, p&lt;0.001). Conversely, FFR alone did not predict revascularisation outcomes (AUC 0.54, 95% CI 0.50-0.57). PPG influenced treatment decisions in 14% of patients, redirecting them from PCI to alternative treatment modalities. Periprocedural myocardial infarction occurred more frequently in patients with low PPG (&lt;0.62) compared to those with focal disease (OR 1.71, 95% CI: 1.00-2.97).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Pathophysiological CAD patterns distinctly affect the safety and effectiveness of PCI. The PPG showed an excellent predictive capacity for optimal revascularisation and demonstrated added value compared to a FFR measurement.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38742491/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240515061000&v=2.18.0.post9+e462414">38742491</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069450>10.1161/CIRCULATIONAHA.124.069450</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38742491</guid>
<pubDate>Tue, 14 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Carlos Collet</dc:creator>
<dc:creator>Daniel Munhoz</dc:creator>
<dc:creator>Takuya Mizukami</dc:creator>
<dc:creator>Jeroen Sonck</dc:creator>
<dc:creator>Hitoshi Matsuo</dc:creator>
<dc:creator>Toshiro Shinke</dc:creator>
<dc:creator>Hirohiko Ando</dc:creator>
<dc:creator>Brian Ko</dc:creator>
<dc:creator>Simone Biscaglia</dc:creator>
<dc:creator>Fernando Rivero</dc:creator>
<dc:creator>Thomas Engstrøm</dc:creator>
<dc:creator>Ketina Arslani</dc:creator>
<dc:creator>Antonio Maria Leone</dc:creator>
<dc:creator>Lokien X van Nunen</dc:creator>
<dc:creator>William F Fearon</dc:creator>
<dc:creator>Evald Høj Christiansen</dc:creator>
<dc:creator>Stephane Fournier</dc:creator>
<dc:creator>Liyew Desta</dc:creator>
<dc:creator>Andy Yong</dc:creator>
<dc:creator>Julien Adjej</dc:creator>
<dc:creator>Javier Escaned</dc:creator>
<dc:creator>Masafumi Nakayama</dc:creator>
<dc:creator>Ashkan Eftekhari</dc:creator>
<dc:creator>Frederik M Zimmermann</dc:creator>
<dc:creator>Koshiro Sakai</dc:creator>
<dc:creator>Tatyana Storozhenko</dc:creator>
<dc:creator>Bruno R da Costa</dc:creator>
<dc:creator>Gianluca Campo</dc:creator>
<dc:creator>Nick E J West</dc:creator>
<dc:creator>Tom De Potter</dc:creator>
<dc:creator>Ward Heggermont</dc:creator>
<dc:creator>Dimitri Buytaert</dc:creator>
<dc:creator>Jozef Bartunek</dc:creator>
<dc:creator>Colin Berry</dc:creator>
<dc:creator>Damien Collison</dc:creator>
<dc:creator>Thomas Johnson</dc:creator>
<dc:creator>Tetsuya Amano</dc:creator>
<dc:creator>Divaka Perera</dc:creator>
<dc:creator>Allen Jeremias</dc:creator>
<dc:creator>Ziad Ali</dc:creator>
<dc:creator>Nico H J Pijls</dc:creator>
<dc:creator>Bernard De Bruyne</dc:creator>
<dc:creator>Nils P Johnson</dc:creator>
<dc:date>2024-05-14</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Influence of Pathophysiological Patterns of Coronary Artery Disease on Immediate Percutaneous Coronary Intervention Outcomes</dc:title>
<dc:identifier>pmid:38742491</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069450</dc:identifier>
</item>
<item>
<title>Mitral valve prolapse: arrhythmic risk during pregnancy and postpartum</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38740526/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240515061000&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: The perinatal period could impose increased risk of malignant VA in women with high-risk AMVP. The data may provide general guidance for pre-conception counselling and for nuanced shared decision-making between patients and clinicians.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 May 14:ehae224. doi: 10.1093/eurheartj/ehae224. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Arrhythmic mitral valve prolapse (AMVP) is linked to life-threatening ventricular arrhythmias (VAs), and young women are considered at high risk. Cases of AMVP in women with malignant VA during pregnancy have emerged, but the arrhythmic risk during pregnancy is unknown. The authors aimed to describe features of women with high-risk AMVP who developed malignant VA during the perinatal period and to assess if pregnancy and the postpartum period were associated with a higher risk of malignant VA.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This retrospective international multi-centre case series included high-risk women with AMVP who experienced malignant VA and at least one pregnancy. Malignant VA included ventricular fibrillation, sustained ventricular tachycardia, or appropriate shock from an implantable cardioverter defibrillator. The authors compared the incidence of malignant VA in non-pregnant periods and perinatal period; the latter defined as occurring during pregnancy and within 6 months after delivery.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The authors included 18 women with AMVP from 11 centres. During 7.5 (interquartile range 5.8-16.6) years of follow-up, 37 malignant VAs occurred, of which 18 were pregnancy related occurring in 13 (72%) unique patients. Pregnancy and 6 months after delivery showed increased incidence rate of malignant VA compared to the non-pregnancy period (univariate incidence rate ratio 2.66, 95% confidence interval 1.23-5.76).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The perinatal period could impose increased risk of malignant VA in women with high-risk AMVP. The data may provide general guidance for pre-conception counselling and for nuanced shared decision-making between patients and clinicians.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38740526/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240515061000&v=2.18.0.post9+e462414">38740526</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae224>10.1093/eurheartj/ehae224</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38740526</guid>
<pubDate>Mon, 13 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Avi Sabbag</dc:creator>
<dc:creator>Eivind W Aabel</dc:creator>
<dc:creator>Anna Isotta Castrini</dc:creator>
<dc:creator>Konstantinos C Siontis</dc:creator>
<dc:creator>Mikael Laredo</dc:creator>
<dc:creator>Jacky Nizard</dc:creator>
<dc:creator>Guillaume Duthoit</dc:creator>
<dc:creator>Samuel Asirvatham</dc:creator>
<dc:creator>Ojasay Sehrawat</dc:creator>
<dc:creator>Feddo P Kirkels</dc:creator>
<dc:creator>Philippe J van Rosendael</dc:creator>
<dc:creator>Roy Beinart</dc:creator>
<dc:creator>Moshe Rav Acha</dc:creator>
<dc:creator>Petr Peichl</dc:creator>
<dc:creator>Han S Lim</dc:creator>
<dc:creator>Christian Sohns</dc:creator>
<dc:creator>Raphael Martins</dc:creator>
<dc:creator>Jonaz Font</dc:creator>
<dc:creator>Nguyen N K Truong</dc:creator>
<dc:creator>Mette Estensen</dc:creator>
<dc:creator>Kristina H Haugaa</dc:creator>
<dc:date>2024-05-13</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Mitral valve prolapse: arrhythmic risk during pregnancy and postpartum</dc:title>
<dc:identifier>pmid:38740526</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae224</dc:identifier>
</item>
<item>
<title>Arrhythmic risk in young women with mitral valve prolapse: keep your eyes open but don't jump at every shadow</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38740523/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240515061000&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 May 14:ehae246. doi: 10.1093/eurheartj/ehae246. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38740523/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240515061000&v=2.18.0.post9+e462414">38740523</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae246>10.1093/eurheartj/ehae246</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38740523</guid>
<pubDate>Mon, 13 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Katja Zeppenfeld</dc:creator>
<dc:creator>Marta de Riva</dc:creator>
<dc:date>2024-05-13</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Arrhythmic risk in young women with mitral valve prolapse: keep your eyes open but don't jump at every shadow</dc:title>
<dc:identifier>pmid:38740523</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae246</dc:identifier>
</item>
<item>
<title>Myocarditis diagnosis: harnessing order amongst heterogeneity through collaboration</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38740520/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240515061000&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 May 14:ehae220. doi: 10.1093/eurheartj/ehae220. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38740520/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240515061000&v=2.18.0.post9+e462414">38740520</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae220>10.1093/eurheartj/ehae220</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38740520</guid>
<pubDate>Mon, 13 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Tahir S Kafil</dc:creator>
<dc:creator>Peter P Liu</dc:creator>
<dc:date>2024-05-13</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Myocarditis diagnosis: harnessing order amongst heterogeneity through collaboration</dc:title>
<dc:identifier>pmid:38740520</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae220</dc:identifier>
</item>
<item>
<title>Highlights From the &lt;em>;Circulation&lt;/em>; Family of Journals</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38739713/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240515061000&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Feb 20;149(8):627-632. doi: 10.1161/CIRCULATIONAHA.124.068812. Epub 2024 Feb 20.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38739713/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240515061000&v=2.18.0.post9+e462414">38739713</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.068812>10.1161/CIRCULATIONAHA.124.068812</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38739713</guid>
<pubDate>Mon, 13 May 2024 06:00:00 -0400</pubDate>
<dc:date>2024-05-13</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Highlights From the &lt;em>;Circulation&lt;/em>; Family of Journals</dc:title>
<dc:identifier>pmid:38739713</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.068812</dc:identifier>
</item>
<item>
<title>Correction to: 2023 Scientific Sessions Abstract 18248</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38739712/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240515061000&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Feb 20;149(8):e935. doi: 10.1161/CIR.0000000000001215. Epub 2024 Feb 20.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38739712/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240515061000&v=2.18.0.post9+e462414">38739712</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001215>10.1161/CIR.0000000000001215</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38739712</guid>
<pubDate>Mon, 13 May 2024 06:00:00 -0400</pubDate>
<dc:date>2024-05-13</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: 2023 Scientific Sessions Abstract 18248</dc:title>
<dc:identifier>pmid:38739712</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001215</dc:identifier>
</item>
<item>
<title>Is There a Role for Calcium Channel Blockers in the Contemporary Treatment Paradigm for Pulmonary Arterial Hypertension?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38739700/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240515061000&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 May 14;149(20):1565-1567. doi: 10.1161/CIRCULATIONAHA.124.069124. Epub 2024 May 13.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38739700/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240515061000&v=2.18.0.post9+e462414">38739700</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069124>10.1161/CIRCULATIONAHA.124.069124</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38739700</guid>
<pubDate>Mon, 13 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Lewis J Rubin</dc:creator>
<dc:date>2024-05-13</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Is There a Role for Calcium Channel Blockers in the Contemporary Treatment Paradigm for Pulmonary Arterial Hypertension?</dc:title>
<dc:identifier>pmid:38739700</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069124</dc:identifier>
</item>
<item>
<title>Correction to: An Aspirin-Free Versus Dual Antiplatelet Strategy for Coronary Stenting: STOPDAPT-3 Randomized Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38739699/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240515061000&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 May 14;149(20):e1189-e1190. doi: 10.1161/CIR.0000000000001255. Epub 2024 May 13.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38739699/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240515061000&v=2.18.0.post9+e462414">38739699</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001255>10.1161/CIR.0000000000001255</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38739699</guid>
<pubDate>Mon, 13 May 2024 06:00:00 -0400</pubDate>
<dc:date>2024-05-13</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: An Aspirin-Free Versus Dual Antiplatelet Strategy for Coronary Stenting: STOPDAPT-3 Randomized Trial</dc:title>
<dc:identifier>pmid:38739699</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001255</dc:identifier>
</item>
<item>
<title>Unraveling the Complex Relationship Between Gut Microbiome and Cardiovascular Diseases</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38739698/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240515061000&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 May 14;149(20):1543-1545. doi: 10.1161/CIRCULATIONAHA.123.067547. Epub 2024 May 13.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38739698/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240515061000&v=2.18.0.post9+e462414">38739698</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067547>10.1161/CIRCULATIONAHA.123.067547</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38739698</guid>
<pubDate>Mon, 13 May 2024 06:00:00 -0400</pubDate>
<dc:creator>W H Wilson Tang</dc:creator>
<dc:creator>Stanley L Hazen</dc:creator>
<dc:date>2024-05-13</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Unraveling the Complex Relationship Between Gut Microbiome and Cardiovascular Diseases</dc:title>
<dc:identifier>pmid:38739698</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067547</dc:identifier>
</item>
<item>
<title>Closure of Coal-Burning Plant in Pittsburgh Linked to Big Reductions in Heart-Related Emergency Department Visits and Hospitalizations</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38739697/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240515061000&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 May 14;149(20):1611-1613. doi: 10.1161/CIRCULATIONAHA.123.067602. Epub 2024 May 13.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38739697/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240515061000&v=2.18.0.post9+e462414">38739697</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067602>10.1161/CIRCULATIONAHA.123.067602</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38739697</guid>
<pubDate>Mon, 13 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Bridget M Kuehn</dc:creator>
<dc:date>2024-05-13</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Closure of Coal-Burning Plant in Pittsburgh Linked to Big Reductions in Heart-Related Emergency Department Visits and Hospitalizations</dc:title>
<dc:identifier>pmid:38739697</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067602</dc:identifier>
</item>
<item>
<title>Win Ratio: A Seductive But Potentially Misleading Method for Evaluating Evidence from Clinical Trials</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38739696/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240515061000&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 May 14;149(20):1546-1548. doi: 10.1161/CIRCULATIONAHA.123.067786. Epub 2024 May 13.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38739696/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240515061000&v=2.18.0.post9+e462414">38739696</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067786>10.1161/CIRCULATIONAHA.123.067786</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38739696</guid>
<pubDate>Mon, 13 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Javed Butler</dc:creator>
<dc:creator>Norman Stockbridge</dc:creator>
<dc:creator>Milton Packer</dc:creator>
<dc:date>2024-05-13</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Win Ratio: A Seductive But Potentially Misleading Method for Evaluating Evidence from Clinical Trials</dc:title>
<dc:identifier>pmid:38739696</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067786</dc:identifier>
</item>
<item>
<title>Metabolic Reprogramming: A Byproduct or a Driver of Cardiomyocyte Proliferation?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38739695/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240515061000&amp;v=2.18.0.post9+e462414
      <description>Defining mechanisms of cardiomyocyte proliferation should guide the understanding of endogenous cardiac regeneration and could lead to novel treatments for diseases such as myocardial infarction. In the neonatal heart, energy metabolic reprogramming (phenotypic alteration of glucose, fatty acid, and amino acid metabolism) parallels cell cycle arrest of cardiomyocytes. The metabolic reprogramming occurring shortly after birth is associated with alterations in blood oxygen levels, metabolic...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 May 14;149(20):1598-1610. doi: 10.1161/CIRCULATIONAHA.123.065880. Epub 2024 May 13.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Defining mechanisms of cardiomyocyte proliferation should guide the understanding of endogenous cardiac regeneration and could lead to novel treatments for diseases such as myocardial infarction. In the neonatal heart, energy metabolic reprogramming (phenotypic alteration of glucose, fatty acid, and amino acid metabolism) parallels cell cycle arrest of cardiomyocytes. The metabolic reprogramming occurring shortly after birth is associated with alterations in blood oxygen levels, metabolic substrate availability, hemodynamic stress, and hormone release. In the adult heart, myocardial infarction causes metabolic reprogramming but these changes cannot stimulate sufficient cardiomyocyte proliferation to replace those lost by the ischemic injury. Some putative pro-proliferative interventions can induce the metabolic reprogramming. Recent data show that altering the metabolic enzymes PKM2 [pyruvate kinase 2], LDHA [lactate dehydrogenase A], PDK4 [pyruvate dehydrogenase kinase 4], SDH [succinate dehydrogenase], CPT1b [carnitine palmitoyl transferase 1b], or HMGCS2 [3-hydroxy-3-methylglutaryl-CoA synthase 2] is sufficient to partially reverse metabolic reprogramming and promotes adult cardiomyocyte proliferation. How metabolic reprogramming regulates cardiomyocyte proliferation is not clearly defined. The possible mechanisms involve biosynthetic pathways from the glycolysis shunts and the epigenetic regulation induced by metabolic intermediates. Metabolic manipulation could represent a new approach to stimulate cardiac regeneration; however, the efficacy of these manipulations requires optimization, and novel molecular targets need to be defined. In this review, we summarize the features, triggers, and molecular regulatory networks responsible for metabolic reprogramming and discuss the current understanding of metabolic reprogramming as a critical determinant of cardiomyocyte proliferation.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38739695/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240515061000&v=2.18.0.post9+e462414">38739695</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065880>10.1161/CIRCULATIONAHA.123.065880</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38739695</guid>
<pubDate>Mon, 13 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Xiaokang Chen</dc:creator>
<dc:creator>Hao Wu</dc:creator>
<dc:creator>Ya Liu</dc:creator>
<dc:creator>Lingyan Liu</dc:creator>
<dc:creator>Steven R Houser</dc:creator>
<dc:creator>Wei Eric Wang</dc:creator>
<dc:date>2024-05-13</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Metabolic Reprogramming: A Byproduct or a Driver of Cardiomyocyte Proliferation?</dc:title>
<dc:identifier>pmid:38739695</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065880</dc:identifier>
</item>





























</channel>
</rss>